Andersen G S, Hartling O J, Hein H O, Leth A
Dan Med Bull. 1985 Oct;32(5):280-3.
The long term effects on blood pressure, body fluid volumes, glomerular filtration rate and plasma renin concentration were studied in 11 patients with essential hypertension during treatment with prizidilol, which is an antihypertensive compound with combined vasodilatator and beta-adrenoceptor blocking actions. After the patients had been treated for four weeks with placebo, the active treatment was given for 12 weeks. Prizidilol reduced both supine and erect blood pressure by 26/14 mmHg (p less than 0.01) and 24/16 mmHg (p less than 0.01) respectively, without inducing significant changes in heart rate. Plasma volume increased significantly by eight percent (p less than 0.02), whereas the increase in extracellular fluid volume was insignificant. Glomerular filtration rate decreased by 4 ml/min./1.73 m2 (p less than 0.02). Plasma renin concentration was unchanged. Prizidilol was tolerated well, but six patients developed oedema and gained weight, which necessitated addition of diuretics in three patients.
对11例原发性高血压患者使用普齐地洛进行治疗,研究该药对血压、体液容量、肾小球滤过率和血浆肾素浓度的长期影响。普齐地洛是一种具有血管舒张和β-肾上腺素能受体阻断联合作用的抗高血压化合物。患者先用安慰剂治疗4周,然后给予12周的有效治疗。普齐地洛使仰卧位血压和直立位血压分别降低26/14 mmHg(p<0.01)和24/16 mmHg(p<0.01),且未引起心率显著变化。血浆容量显著增加8%(p<0.02),而细胞外液容量增加不显著。肾小球滤过率降低4 ml/min./1.73 m2(p<0.02)。血浆肾素浓度未改变。普齐地洛耐受性良好,但6例患者出现水肿并体重增加,其中3例患者需要加用利尿剂。